+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Retinitis Pigmentosa Market by Type (Autosomal Dominant Retinitis Pigmentosa, Autosomal Recessive Retinitis Pigmentosa, X-linked Retinitis Pigmentosa), Offering (Diagnosis, Treatment), End-User - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Retinitis Pigmentosa Market by Type (Autosomal Dominant Retinitis Pigmentosa, Autosomal Recessive Retinitis Pigmentosa, X-linked Retinitis Pigmentosa), Offering (Diagnosis, Treatment), End-User - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Sale

Retinitis Pigmentosa Market by Type (Autosomal Dominant Retinitis Pigmentosa, Autosomal Recessive Retinitis Pigmentosa, X-linked Retinitis Pigmentosa), Offering (Diagnosis, Treatment), End-User - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 194 Pages
  • August 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 5967695
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Retinitis Pigmentosa is a severe hereditary retinal disorder creating lasting challenges for healthcare systems and patient communities. The Retinitis Pigmentosa market is evolving, shaped by medical innovation, regulatory adaptation, and emerging patient needs.

Market Snapshot: Retinitis Pigmentosa Market

The Retinitis Pigmentosa market grew from USD 7.50 billion in 2024 to USD 7.96 billion in 2025. It is expected to continue growing at a CAGR of 6.32%, reaching USD 10.84 billion by 2030. Growth is being propelled by advancements in gene therapy, diagnostic imaging, and regulatory support for orphan and breakthrough designations. This environment is fostering partnerships, domestic capacity investments, and improving patient access pathways across developed and emerging economies.

Scope & Segmentation

  • Type: Autosomal Dominant Retinitis Pigmentosa, Autosomal Recessive Retinitis Pigmentosa, X-linked Retinitis Pigmentosa
  • Offering: Diagnostic technologies including Electroretinography, Fundus Photography, Optical Coherence Tomography; Treatment approaches such as Gene Therapy, Retinal Implantation, Stem Cell Therapy
  • End-User: Diagnostic Centers, Hospitals & Clinics, Specialty Eye Care Centers
  • Regions: Americas (United States including California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada; Mexico; Brazil; Argentina), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
  • Key Companies: 4D Molecular Therapeutics, Inc.; Astellas Pharma Inc.; Axovia Therapeutics; Beacon Therapeutics Limited; BIOGEN INC.; Clino Corporation; Editas Medicine, Inc.; GENSIGHT BIOLOGICS; Horama SA; jCyte, Inc.; Johnson & Johnson Services, Inc.; Kiora Pharmaceuticals, Inc.; MeiraGTx Holdings PLC; Mimetogen Pharmaceuticals; Nacuity Pharmaceuticals; Nanoscope Therapeutics, Inc.; Novartis AG; Ocugen, Inc.; Oxford Biomedica PLC; Precision BioSciences, Inc.; ProQR Therapeutics N.V.; Sanofi S.A.; Santen Pharmaceutical Co., Ltd.; Skyline Therapeutics; Spark Therapeutics, Inc.; Sun Pharmaceutical Industries Ltd.; Takeda Pharmaceutical Company Limited; ViGeneron GmbH

Key Takeaways for Senior Decision-Makers

  • Gene therapy and advanced imaging drive new standards in early diagnosis and personalize intervention strategies across Retinitis Pigmentosa market segments.
  • Genetic diversity, including autosomal dominant, autosomal recessive, and X-linked forms, compels tailored clinical development and resource planning for optimal patient outcomes.
  • Specialty eye care centers are centralizing care delivery by integrating multimodal diagnostics and cutting-edge therapeutics under unified management, streamlining the patient experience.
  • Partnerships between biotechs, diagnostics manufacturers, and software firms are accelerating platform integration, real-time analytics, and data-driven decision-making.
  • Patient advocacy is reshaping research direction and access policies, while value-based contracting supports sustainable reimbursement for innovative treatments.
  • Regional infrastructure, from clinical trial hubs in developed regions to public-private partnerships in Asia-Pacific, is influencing rollout speed and market penetration.

Tariff Impact in 2025

The 2025 US tariffs on imported gene therapy vectors, precision imaging equipment, and vector production components have resulted in higher operating costs for pharmaceutical developers and diagnostic providers. Firms are responding by ramping up domestic manufacturing, investing in local vector production, and reevaluating supply chains. Demand for US-based contract development and manufacturing organizations has grown, while reimbursement strategies and supplier partnerships are under review to abate rising costs and ensure market continuity.

Methodology & Data Sources

This analysis draws on primary research including expert interviews and discussions with industry stakeholders. Secondary data is sourced from peer-reviewed journals, regulatory documents, annual reports, clinical trial registries, and trusted market databases. Data was validated through statistical triangulation and advisory board consultations to deliver a reliable market view.

Why This Report Matters

  • Delivers a strategic, segmented framework for understanding market drivers, barriers, and opportunities specific to Retinitis Pigmentosa.
  • Equips decision-makers with intelligence to guide investment planning, pipeline prioritization, and stakeholder engagement.
  • Supports supply chain resilience, value-based contracting, and localization strategies in an evolving regulatory environment.

Conclusion

The Retinitis Pigmentosa market is entering a rapid phase of transformation, marked by scientific progress, shifting economics, and new collaboration models. Stakeholders who act on segmented intelligence are best positioned to drive innovation, efficiency, and improved patient care.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Retinitis Pigmentosa Market, by Type
8.1. Introduction
8.2. Autosomal Dominant Retinitis Pigmentosa
8.3. Autosomal Recessive Retinitis Pigmentosa
8.4. X-linked Retinitis Pigmentosa
9. Retinitis Pigmentosa Market, by Offering
9.1. Introduction
9.2. Diagnosis
9.2.1. Electroretinography
9.2.2. Fundus Photography
9.2.3. Optical Coherence Tomography
9.3. Treatment
9.3.1. Gene Therapy
9.3.2. Retinal Implantation
9.3.3. Stem Cell Therapy
10. Retinitis Pigmentosa Market, by End-User
10.1. Introduction
10.2. Diagnostic Centers
10.3. Hospitals & Clinics
10.4. Specialty Eye Care Centers
11. Americas Retinitis Pigmentosa Market
11.1. Introduction
11.2. United States
11.3. Canada
11.4. Mexico
11.5. Brazil
11.6. Argentina
12. Europe, Middle East & Africa Retinitis Pigmentosa Market
12.1. Introduction
12.2. United Kingdom
12.3. Germany
12.4. France
12.5. Russia
12.6. Italy
12.7. Spain
12.8. United Arab Emirates
12.9. Saudi Arabia
12.10. South Africa
12.11. Denmark
12.12. Netherlands
12.13. Qatar
12.14. Finland
12.15. Sweden
12.16. Nigeria
12.17. Egypt
12.18. Turkey
12.19. Israel
12.20. Norway
12.21. Poland
12.22. Switzerland
13. Asia-Pacific Retinitis Pigmentosa Market
13.1. Introduction
13.2. China
13.3. India
13.4. Japan
13.5. Australia
13.6. South Korea
13.7. Indonesia
13.8. Thailand
13.9. Philippines
13.10. Malaysia
13.11. Singapore
13.12. Vietnam
13.13. Taiwan
14. Competitive Landscape
14.1. Market Share Analysis, 2024
14.2. FPNV Positioning Matrix, 2024
14.3. Competitive Analysis
14.3.1. 4D Molecular Therapeutics, Inc.
14.3.2. Astellas Pharma Inc.
14.3.3. Axovia Therapeutics
14.3.4. Beacon Therapeutics Limited
14.3.5. BIOGEN INC.
14.3.6. Clino Corporation
14.3.7. Editas Medicine, Inc.
14.3.8. GENSIGHT BIOLOGICS
14.3.9. Horama SA
14.3.10. jCyte, Inc.
14.3.11. Johnson & Johnson Services, Inc.
14.3.12. Kiora Pharmaceuticals, Inc.
14.3.13. MeiraGTx Holdings PLC
14.3.14. Mimetogen Pharmaceuticals
14.3.15. Nacuity Pharmaceuticals
14.3.16. Nanoscope Therapeutics, Inc.
14.3.17. Novartis AG
14.3.18. Ocugen, Inc.
14.3.19. Oxford Biomedica PLC
14.3.20. Precision BioSciences, Inc.
14.3.21. ProQR Therapeutics N.V.
14.3.22. Sanofi S.A.
14.3.23. Santen Pharmaceutical Co., Ltd.
14.3.24. Skyline Therapeutics
14.3.25. Spark Therapeutics, Inc.
14.3.26. Sun Pharmaceutical Industries Ltd.
14.3.27. Takeda Pharmaceutical Company Limited
14.3.28. ViGeneron GmbH
15. ResearchAI
16. ResearchStatistics
17. ResearchContacts
18. ResearchArticles
19. Appendix
List of Figures
FIGURE 1. RETINITIS PIGMENTOSA MARKET MULTI-CURRENCY
FIGURE 2. RETINITIS PIGMENTOSA MARKET MULTI-LANGUAGE
FIGURE 3. RETINITIS PIGMENTOSA MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024 VS 2030 (%)
FIGURE 10. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. RETINITIS PIGMENTOSA MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. RETINITIS PIGMENTOSA MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. RETINITIS PIGMENTOSA MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY AUTOSOMAL DOMINANT RETINITIS PIGMENTOSA, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY AUTOSOMAL RECESSIVE RETINITIS PIGMENTOSA, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY X-LINKED RETINITIS PIGMENTOSA, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY ELECTRORETINOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY FUNDUS PHOTOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY RETINAL IMPLANTATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY SPECIALTY EYE CARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 31. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 32. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 33. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 37. CANADA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 38. CANADA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 39. CANADA RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 40. CANADA RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 41. CANADA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 42. MEXICO RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 43. MEXICO RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 44. MEXICO RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 45. MEXICO RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 46. MEXICO RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 47. BRAZIL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 48. BRAZIL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 49. BRAZIL RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 51. BRAZIL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 52. ARGENTINA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 53. ARGENTINA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 54. ARGENTINA RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 56. ARGENTINA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 57. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 58. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 59. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 60. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 61. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 62. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 63. UNITED KINGDOM RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 64. UNITED KINGDOM RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 65. UNITED KINGDOM RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 66. UNITED KINGDOM RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 67. UNITED KINGDOM RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 68. GERMANY RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 69. GERMANY RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 70. GERMANY RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 71. GERMANY RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 72. GERMANY RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 73. FRANCE RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 74. FRANCE RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 75. FRANCE RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 76. FRANCE RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 77. FRANCE RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 78. RUSSIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 79. RUSSIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 80. RUSSIA RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 81. RUSSIA RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 82. RUSSIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 83. ITALY RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 84. ITALY RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 85. ITALY RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 86. ITALY RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 87. ITALY RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 88. SPAIN RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 89. SPAIN RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 90. SPAIN RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 91. SPAIN RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 92. SPAIN RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 93. UNITED ARAB EMIRATES RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 94. UNITED ARAB EMIRATES RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 95. UNITED ARAB EMIRATES RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 96. UNITED ARAB EMIRATES RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 97. UNITED ARAB EMIRATES RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 98. SAUDI ARABIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 99. SAUDI ARABIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 100. SAUDI ARABIA RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 101. SAUDI ARABIA RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 102. SAUDI ARABIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 103. SOUTH AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 104. SOUTH AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 105. SOUTH AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 106. SOUTH AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 107. SOUTH AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 108. DENMARK RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 109. DENMARK RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 110. DENMARK RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 111. DENMARK RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 112. DENMARK RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 113. NETHERLANDS RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 114. NETHERLANDS RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 115. NETHERLANDS RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 116. NETHERLANDS RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 117. NETHERLANDS RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 118. QATAR RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 119. QATAR RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 120. QATAR RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 121. QATAR RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 122. QATAR RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 123. FINLAND RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 124. FINLAND RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 125. FINLAND RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 126. FINLAND RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 127. FINLAND RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 128. SWEDEN RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 129. SWEDEN RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 130. SWEDEN RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 131. SWEDEN RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 132. SWEDEN RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 133. NIGERIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 134. NIGERIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 135. NIGERIA RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 136. NIGERIA RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 137. NIGERIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 138. EGYPT RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 139. EGYPT RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 140. EGYPT RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 141. EGYPT RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 142. EGYPT RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 143. TURKEY RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 144. TURKEY RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 145. TURKEY RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 146. TURKEY RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 147. TURKEY RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 148. ISRAEL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 149. ISRAEL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 150. ISRAEL RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 151. ISRAEL RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 152. ISRAEL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 153. NORWAY RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 154. NORWAY RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 155. NORWAY RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 156. NORWAY RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 157. NORWAY RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 158. POLAND RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 159. POLAND RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 160. POLAND RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 161. POLAND RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 162. POLAND RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 163. SWITZERLAND RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 164. SWITZERLAND RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 165. SWITZERLAND RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 166. SWITZERLAND RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 167. SWITZERLAND RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 168. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 169. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 170. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 171. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 172. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 173. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 174. CHINA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 175. CHINA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 176. CHINA RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 177. CHINA RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 178. CHINA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 179. INDIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 180. INDIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 181. INDIA RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 182. INDIA RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 183. INDIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 184. JAPAN RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 185. JAPAN RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 186. JAPAN RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 187. JAPAN RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 188. JAPAN RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 189. AUSTRALIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 190. AUSTRALIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 191. AUSTRALIA RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 192. AUSTRALIA RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 193. AUSTRALIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 194. SOUTH KOREA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 195. SOUTH KOREA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 196. SOUTH KOREA RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 197. SOUTH KOREA RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 198. SOUTH KOREA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 199. INDONESIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 200. INDONESIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 201. INDONESIA RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 202. INDONESIA RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 203. INDONESIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 204. THAILAND RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 205. THAILAND RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 206. THAILAND RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 207. THAILAND RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 208. THAILAND RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 209. PHILIPPINES RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 210. PHILIPPINES RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 211. PHILIPPINES RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 212. PHILIPPINES RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 213. PHILIPPINES RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 214. MALAYSIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 215. MALAYSIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 216. MALAYSIA RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 217. MALAYSIA RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 218. MALAYSIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 219. SINGAPORE RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 220. SINGAPORE RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 221. SINGAPORE RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 222. SINGAPORE RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 223. SINGAPORE RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 224. VIETNAM RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 225. VIETNAM RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 226. VIETNAM RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 227. VIETNAM RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 228. VIETNAM RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 229. TAIWAN RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 230. TAIWAN RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
TABLE 231. TAIWAN RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 232. TAIWAN RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 233. TAIWAN RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 234. RETINITIS PIGMENTOSA MARKET SHARE, BY KEY PLAYER, 2024
TABLE 235. RETINITIS PIGMENTOSA MARKET, FPNV POSITIONING MATRIX, 2024

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Retinitis Pigmentosa market report include:
  • 4D Molecular Therapeutics, Inc.
  • Astellas Pharma Inc.
  • Axovia Therapeutics
  • Beacon Therapeutics Limited
  • BIOGEN INC.
  • Clino Corporation
  • Editas Medicine, Inc.
  • GENSIGHT BIOLOGICS
  • Horama SA
  • jCyte, Inc.
  • Johnson & Johnson Services, Inc.
  • Kiora Pharmaceuticals, Inc.
  • MeiraGTx Holdings PLC
  • Mimetogen Pharmaceuticals
  • Nacuity Pharmaceuticals
  • Nanoscope Therapeutics, Inc.
  • Novartis AG
  • Ocugen, Inc.
  • Oxford Biomedica PLC
  • Precision BioSciences, Inc.
  • ProQR Therapeutics N.V.
  • Sanofi S.A.
  • Santen Pharmaceutical Co., Ltd.
  • Skyline Therapeutics
  • Spark Therapeutics, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • ViGeneron GmbH

Table Information

Report AttributeDetails
No. of Pages194
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 7.96 Billion
Forecasted Market Value ( USD ) by 2030 $ 10.84 Billion
Compound Annual Growth Rate6.3%
Regions CoveredGlobal, United States
No. of Companies Mentioned29

Related Topics

Related Reports

Retinitis Pigmentosa Market Opportunities and Strategies to 2034 - Product Image

Retinitis Pigmentosa Market Opportunities and Strategies to 2034

  • Report
  • 337 Pages
  • Global
From
Retinitis Pigmentosa Market Report 2025 - Product Image

Retinitis Pigmentosa Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Retinitis Pigmentosa Treatment Market Report and Forecast 2024-2032 - Product Image

Retinitis Pigmentosa Treatment Market Report and Forecast 2024-2032

  • Report
  • 250 Pages
  • Global
From
Retinitis Pigmentosa Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application - Product Image

Retinitis Pigmentosa Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

  • Report
  • 71 Pages
  • Global
From
AAV for the Hereditary Retinal Diseases - Competitive Landscape, 2025 - Product Image

AAV for the Hereditary Retinal Diseases - Competitive Landscape, 2025

  • Report
  • 280 Pages
  • Global
From

About the Retinitis Pigmentosa Market

The Retinitis Pigmentosa (RP) market within the context of optical health pertains to the diagnosis, treatment, and management of this progressive genetic eye condition. Because RP leads to the degeneration of photoreceptor cells in the retina, culminating in vision loss, the market includes a variety of medical devices, therapeutic drugs, and supportive technologies. Advances in optogenetics, gene therapy, and electronic visual aids have pushed the boundaries of what can be offered to patients with this condition. Additionally, the development of specialized supplements that aim to preserve vision and the creation of assistive devices cater to the lifestyle needs of those affected. Specialists such as ophthalmologists and optometrists play key roles in managing the condition, which often necessitates a collaborative approach that includes genetic counselors and low-vision rehabilitation services. Several companies participate in the Retinitis Pigmentosa market, focusing on innovative solutions for managing and potentially treating this ocular disease. Spark Therapeutics is noted for its gene therapy research, while ProQR Therapeutics specializes in RNA-based treatments. Second Sight Medical Products develops implantable visual prosthetics, and OrCam creates advanced assistive technology devices that utilize artificial intelligence to assist those with visual impairments. These companies, among others, are at the forefront of efforts to improve the vision and quality of life for individuals affected by Retinitis Pigmentosa. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.